Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis

Journal of the American Academy of Dermatology

Volumn 56, Issue 4, 2007, Pages 710-712

  High, Whitney A ^a   Ayers, Reed A ^b   Cowper, Shawn E ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b Department of Metallurgical and Materials Engineering   (United States)

^c YALE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM;

ACTINIC KERATOSIS; ARTICLE; HISTOPATHOLOGY; HUMAN; MASS SPECTROMETRY; NEPHROGENIC FIBROSING DERMOPATHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SAMPLE SIZE; SAMPLING; SKIN CULTURE;

BIOPSY, NEEDLE; CONTRAST MEDIA; FEMALE; FIBROSIS; GADOLINIUM DTPA; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MASS SPECTROMETRY; RISK ASSESSMENT; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SKIN;

EID: 33947140510     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.01.022     Document Type: Article

References (4)

1. High W.A., Ayers R.A., Chandler J., Zito G., and Cowper S.E. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56 (2007) 21-26
2. White G.W., Gibby W.A., and Tweedle M.F. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 41 (2006) 272-278
3. Idee J.M., Port M., Raynal I., Schaefer M., Le Greneur S., and Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20 (2006) 563-576
4. Center for Drug Evaluation and Research. US Food and Drug Administration World Wide Web site. Public health advisory: public health advisory update on magnetic resonance imaging (MRI) contrast agents containing gadolinium and nephrogenic fibrosing dermopathy (December 22, 2006). Available from: URL:http://www.fda.gov/cder/drug/advisory/gadolinium_agents.htm. Accessed December 30, 2006.